Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.

The secondary objective of the study is to evaluate the safety and efficacy (ORR) of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.
Metastatic Breast Cancer
DRUG: Docetaxel, trastuzumab|DRUG: Pyrotinib
Pharmacokinetic parameter: Cmax of pyrotinib and docetaxel, Peak Plasma Concentration (Cmax) of pyrotinib, Approximately 2 months|Pharmacokinetic parameter: AUC of pyrotinib and docetaxel, Area under the plasma concentration versus time curve (AUC) of pyrotinib and docetaxel, Approximately 2 months
ORR, Objective Response Rate, Approximately 17 months|AEs+SAEs, Adverse Events and Serious Adverse Events, Approximately 17 months|λz, Approximately 6 months|The incidence of≥3 grade diarrhea with different treatment, Approximately 17 months
The primary objective of the study is to study the pharmacokinetics of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.

The secondary objective of the study is to evaluate the safety and efficacy (ORR) of pyrotinib and docetaxel plus Trastuzumab in HER2 Positive MBC.